)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Amarin Corporation
Amarin Corporation (AMRN) investor relations material
Amarin Corporation Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary28 Oct, 2026
Executive summary
First profitable quarter in over two years, with lower operating expenses, positive operating cash flow and $323.4M in cash and short-term investments.
International partner demand grew strongly while U.S. generic competition and pricing pressure weighed on revenue.
Financial highlights
Q3 revenue was $39.6M, down 20% YoY; product revenue fell 24% to $36.9M, while licensing and royalty revenue rose 139% to $2.7M.
Net income was $245K versus a $7.7M net loss; operating loss narrowed to $2.4M from $11.1M.
Operating expenses fell 44% to $18.5M; 9M operating expenses declined 47% to $74.6M.
9M revenue was $126.9M, down 23%; net loss narrowed to $17.9M from $37.6M.
9M operating cash flow was $22.2M versus $8.5M used in the prior-year period; Q3 operating cash flow was $9.2M.
Outlook and guidance
Positive operating cash flow expected for FY 2026, with Q4 cash flow expected to remain positive and further operating expense reductions anticipated, excluding restructuring charges.
U.S. volumes expected to remain broadly stable through year-end 2026; significant exclusive business expected to be retained through year-end.
Global partner-market demand is expected to grow sequentially; revenue timing depends on partner inventory, orders, market access and pricing.
Singapore and South Korea launches are anticipated in 2027; regulatory approvals in the Philippines, Thailand, Vietnam and Malaysia are anticipated by 2030.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Amarin Corporation
- Global IPE demand up 59% and costs down 59%, driving improved margins and cash flow.AMRN
Q2 2026 - Revenue rose 7% as losses narrowed and positive cash flow continued.AMRNQ1 2026
- Proxy covers director elections, compensation, auditor, share issuance, and cost-saving proposals.AMRNProxy filing
- Shareholders will vote on director re-elections, compensation, and key cost-saving governance reforms.AMRNProxy filing
- Q4 2025 revenue hit $49.2M, with major cost cuts and $303M cash fueling 2026 growth.AMRNQ4 2025
- VASCEPA/VAZKEPA targets global growth with focused strategy, strong data, and extended IP runway.AMRNCMD 2024
- Revenue dropped 36% but strong cash and European growth support global expansion.AMRNQ3 2024
- Q2 revenue fell 16% on U.S. generics, but cash and cost controls remain strong.AMRNQ2 2024
- 2024 revenue hit $228.6M, cash $294.2M, with global growth and Nasdaq listing secured.AMRNQ4 2024
Next Amarin Corporation earnings date
Q4 202624 Feb, 2027
Amarin Corporation
Next Amarin Corporation earnings date
Q4 202624 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Amarin Corporation plc is a biopharmaceutical company focused on developing and commercializing therapies for cardiovascular health. The company's primary product is an omega-3-based prescription therapy designed to reduce cardiovascular risk in patients with elevated triglyceride levels. Amarin's research and development efforts center on addressing unmet needs in cardiovascular care through innovative lipid management treatments. The company operates globally, with a focus on expanding its product offerings and advancing cardiovascular treatment options. The company is headquartered in Dublin, Ireland, and its shares are listed on the Nasdaq.